Dare Bioscience, Inc. - DARE Company Short-Term Debt

The credit rating of Dare Bioscience, Inc. (DARE) is based on revenues from the sale of women's health products and royalties. The level of short-term debt load demonstrates price stability, while 0.00 reflects the latest metric level. Financial stability is bolstered by alliances with pharma behemoths to bring products to market and a stable staff of specialized scientists with clinical experience.

DARE (Dare Bioscience) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

Daré Bioscience, Inc. - analytical breakdowns and key metrics (DARE)

- price and consensus price forecast:

Price Chart Daré Bioscience|DARE - Fair Value Consensus

- market capitalization data:

Market Value Dare Bioscience|DARE - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share Daré Bioscience|DARE - Book Capitalization|Market Cap to Net Assets Ratio darebioscience.com|DARE - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Equity Ratio Dare Bioscience, Inc.|DARE - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Dare Bioscience, Inc.|DARE - Company Cumulative Debt|Debt to Book Capitalization Ratio Dare Bioscience|DARE - Company Long-Term Liabilities|Company Short-Term Debts Daré Bioscience

Fundamental company valuation:Daré Bioscience - DARE

Flagship merchandise of Dare Bioscience, Inc.

For women's health innovator Dare Bioscience, Inc. (DARE), the history of short-term credits and loans reflects the ability to fund the development of unique drug delivery systems without critical pressure on liquidity. This indicator aggregates all obligations with a maturity of up to one year, allowing investors to assess default risk and the efficiency of working capital management within the context of capital-intensive medical research.

Competitors of Dare Bioscience, Inc. (DARE)

Company Short-Term Debt Organon (OGN)|TXMD: Company Short-Term Loans and Borrowings|PTN (Palatin) - Company Short-Term Debt